F
Francesco Paolo Schena
Researcher at University of Bari
Publications - 367
Citations - 18414
Francesco Paolo Schena is an academic researcher from University of Bari. The author has contributed to research in topics: Transplantation & Kidney. The author has an hindex of 71, co-authored 352 publications receiving 16969 citations. Previous affiliations of Francesco Paolo Schena include University of Florence & Leiden University Medical Center.
Papers
More filters
Journal ArticleDOI
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
Giovanni Stallone,Antonio Schena,Barbara Infante,Di Paolo S,Antonia Loverre,Maggio G,Elena Ranieri,Loreto Gesualdo,Francesco Paolo Schena,Giuseppe Grandaliano +9 more
TL;DR: Sirolimus inhibits the progression of dermal Kaposi's sarcoma in kidney-transplant recipients while providing effective immunosuppression.
Journal ArticleDOI
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
Piero Ruggenenti,Annalisa Perna,Giulia Gherardi,Giovanni Garini,Carmine Zoccali,Maurizio Salvadori,Francesco Scolari,Francesco Paolo Schena,Giuseppe Remuzzi +8 more
TL;DR: In non-diabetic nephropathies, ACE inhibition confers renoprotection even to patients with non-nephrotic proteinuria, and the rate of decline in GFR and the frequency of ESRF were much lower in stratum 1 than they had been instratum 2.
Journal ArticleDOI
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Francesco Paolo Schena,M.D Pascoe,Josefina Alberú,M Rial,Rainer Oberbauer,Daniel C. Brennan,Josep M. Campistol,Lorraine C. Racusen,Martin S. Polinsky,Robert Goldberg-Alberts,Huihua Li,Joseph Scarola,John F. Neylan +12 more
TL;DR: In this article, the efficacy and safety of converting maintenance renal transplant recipients from calcineurin inhibitors (CNIs) to sirolimus (SRL) was evaluated.
Journal ArticleDOI
Pathogenetic Mechanisms of Diabetic Nephropathy
TL;DR: Because hyperglycemia is the principal factor responsible for structural alterations at the renal level, glycemic control remains the main target of the therapy, whereas pancreas transplantation is the best approach for reducing the renal lesions.
Journal ArticleDOI
Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review
Giovanni F.M. Strippoli,Maria E. Craig,Jonathan J Deeks,Francesco Paolo Schena,Jonathan C. Craig +4 more
TL;DR: Although the survival benefits of ACE inhibitors for patients with diabetic nephropathy are known, the relative effects ofACE inhibitors and AIIRAs on survival are unknown owing to the lack of adequate head to head trials.